Capital Rx Drug Recall Report

OCTOBER 2024

Capital Rx

Welcome to the Capital Rx Drug Recall Report. This report is designed to keep you up to date on the latest FDA Class 1 and Class 2 recalled drugs and market withdrawals that impact our members. It is one of the many ways we, at Capital Rx, demonstrate our commitment to providing clients and partners the tools and resources they desire.

WHO WE ARE

Capital Rx is a full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA), advancing our nation's electronic healthcare infrastructure to improve drug price visibility and patient outcomes. As a Certified B Corp™, Capital Rx is executing its mission through the deployment of JUDI®, the company's cloud-native enterprise health platform, and a Single-Ledger Model™, which increases visibility and reduces variability in drug prices. JUDI connects every aspect of the pharmacy ecosystem in one efficient, scalable platform, servicing over 2.4 million members for Medicare, Medicaid, and commercial plans. Together with our clients, we are reimagining the administration of pharmacy benefits and rebuilding trust in healthcare. **The drug recall report is subject to change: information in this report is current as of **10/16/2024****

Privacy Statement:

This privacy policy describes the types of information we may collect from you or that you may provide when you visit the website cap-rx.com and our practices for collecting, using, maintaining, protecting, and disclosing that information. Capital Rx, Inc. ("we," "our," or "us") is committed to ensuring that your privacy is protected. This policy applies to information we may collect through cap-rx.com, including any services offered on or through cap-rx.com such as the prescription benefit member web portal, and our mobile application accessible at the Google Play Store and iOS App Store under the name Capital Rx (collectively, our "Site").

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
9/26/2024	Market Withdrawal	Oxbryta 500 Mg Tablets	Pfizer Inc.	72786-0101-01	All Lots	Recent data indicating the benefit of Oxbryta does not outweigh the risks for the sickle cell patient population.
9/26/2024	Market Withdrawal	Oxbryta 300 Mg Tbso	Pfizer Inc.	72786-0111-03, 72786-0111-02	All Lots	Recent data indicating the benefit of Oxbryta does not outweigh the risks for the sickle cell patient population.
9/26/2024	Market Withdrawal	Oxbryta 300 Mg Tablets	Pfizer Inc.	72786-0102-02, 72786-0102-03	All Lots	Recent data indicating the benefit of Oxbryta does not outweigh the risks for the sickle cell patient population.

Capital Rx Drug Recall Report

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
10/2/2024	Class 2	Mycophenolate Sodium 360 Mg Delayed Release Tablets	Ascend Laboratories, LLC	67877-0427-12	22123437, 22123438, 22123535, EXP 9/30/24; 22123536, 22123537, 22123538, 22123646, 22123647, EXP 10/31/24; 23120529, 23120530, EXP 1/31/25; 23120703, 23120705, EXP 2/28/25; 23121429, 23121726, 23122049, 23122097, EXP 4/30/25; 23121984, 23121985, 23121986, EXP 5/31/25; 23122325, 23122329, 23122330,23122331, EXP 6/30/26; 23122776, 23122852, 23122853, 23123154, 23123155, EXP 8/31/26; 23123458, EXP 9/30/26	Failing to meet impurity and degradation standards.
10/2/2024	Class 2	Mupirocin 2% Ointment	Glenmark Pharmaceuticals Inc., USA	68462-0180-22	19223615, 19223537, 19223544,19223568, 19223593, 19223641, EXP 08/2024; 19224055,19224281, 19224307, 19224321, 19224341, 19224467, EXP 09/2024; 19224525, 19224542, 19224560,19224580, EXP 10/2024; 19224990, 19224998, 19225014, 19225033, 19225293, 19225304, 19225320, 19225349, 19225367, 19225379, 19225401, EXP 11/2024; 19230115, 19230123, 19230132, 19230137, 19230167, 19230170, EXP 12/2024; 19230572, 19230607, 19230614, 19230628, 19230631, EXP 1/2025; 19230874, 19230925, 19230941, 19230957, 19230976,19231232, 19231238, 19231282, 19231285, EXP 02/2025	The product being subpotent (not strong enough).

Capital Rx Drug Recall Report

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
10/9/2024	Class 2	Atorvastatin Calcium 40 Mg Tablets	Nivagen Pharmaceuticals Inc	75834-0257-01	U24T0408A, EXP: 03/31/2026	The presence of different tablets. A Carbamazepine Extended-Release 400 mg tablet was found in a 1000-count bottle of Atorvastatin Calcium 40 mg Tablets.
10/9/2024	Class 2	Ryaltris 665-25 Mcg/Act Nasal Spray	Glenmark Pharmaceuticals Inc., USA	59467-0700-27	14230425, EXP: NOV-25; 14240024, EXP: DEC-25; 14240029, EXP: DEC-25; 14240076, EXP: JAN-26; 14240082, EXP: JAN-26; 14240090, EXP: JAN-26; 14240100, EXP: JAN-26	A clog in the dip tube, causing the nasal spray not to work.

How do I find out more information about the recall? View the FDA website URL for more information.

RECALL TYPE	DRUG RECALLED	FDA NOTIFICATION URL
Market Withdrawal	Oxbryta 500 Mg Tablets	https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due
Market Withdrawal	Oxbryta 300 Mg Tbso	https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due
Market Withdrawal	Oxbryta 300 Mg Tablets	https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due
Class 2	Mycophenolate Sodium 360 Mg Delayed Release Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=209875
Class 2	Mupirocin 2% Ointment	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=209891
Class 2	Atorvastatin Calcium 40 Mg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=210206
Class 2	Ryaltris 665-25 Mcg/Act Nasal Spray	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=210117